Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia

Zeng, Chengwu; Yu, Xibao; Lai, Jing; Yang, Lijiang; Chen, Shaohua; Li, Yangqiu

doi:10.1186/s13045-015-0223-4

Cited by 98 publications

(79 citation statements)

References 47 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Around the same time, studies showed that the PVT1 gene locus also underwent a variant translocation in human Burkitt’s lymphomas [10, 11]. The PVT1 gene is located on chromosome 8, a recognized cancer risk locus shared with the well-known MYC oncogene_ENREF_12, suggesting that PVT1 is a potential oncogene [12]. In vitro experiments have demonstrated that PVT1 could promote proliferation, migration and invasion of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases

Qin

Lin

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Whether the level of long noncoding RNA plasmacytoma variant translocation 1 gene (lncRNA PVT1) expression influences the clinical development and outcome of human cancers has not been thoroughly elucidated to date. Inconsistencies still exist regarding the associations between PVT1 and the clinicopathological features, including patient survival data. Additionally, the regulatory mechanism of PVT1 among human cancers remains unclear. Methods: we conducted a comprehensive inquiry to verify the implication of PVT1 expression in cancer patients by conducting a meta-analysis of 19 selected studies and The Cancer Genome Atlas (TCGA) database to examine the relationship between PVT1 expression and both the prognosis and clinicopathological features of cancer patients using STATA 12.0. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the potential mRNA target genes of PVT1 gathered from TANRIC and Multi Experiment Matrix (MEM) were performed. Results: The level of PVT1 expression in tumor tissues was higher than in paired non-cancer tissues and was significantly associated with a poorer prognosis in cancer patients. Additionally, overexpression of PVT1 was significantly correlated with histological differentiation, tumor (T) classification, lymph node (N) classification and TNM stages. Furthermore, a total of 462 validated target genes were identified, and the GO and KEGG analyses demonstrated that the validated targets of PVT1 were significantly enriched in several pathways, including the GnRH signaling pathway, the Cytokine-cytokine receptor interaction pathway, the Inflammatory mediator regulation of TRP channels pathway, and the Neuroactive ligand-receptor interaction pathway. Conclusion: PVT1 may serve as a potential biomarker associated with the progression and prognosis of human cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases

Qin

Lin

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…As lncRNAs have emerged as important participants in the pathogenesis and disease progression of AML, [66][67][68][69][70][71][72][73][74] it is likely that profiling of their expression would have significant impact on MDS prognostication. Recently, it has been shown that lncRNA expression signatures were closely associated with specific mutations and a small subset of lncRNAs could predict clinical outcome in cytogenetically normal elderly AML patients, 75 but the clinical significance of lncRNA profiling in MDSs has not yet been reported.…”

Section: Discussionmentioning

confidence: 99%

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes

Yao

Chen

Huang³

et al. 2017

Blood Advances

View full text Add to dashboard Cite

Key Points• Through lncRNA profiling, we identified an MDS patient subset with distinct clinical and mutational patterns along with inferior outcomes.• A concise yet powerful 4-lncRNA risk-scoring system was devised with the potential to improve current MDS risk stratification.Long noncoding RNAs (lncRNAs) not only participate in normal hematopoiesis but also contribute to the pathogenesis of acute leukemia. However, their clinical and prognostic relevance in myelodysplastic syndromes (MDSs) remains unclear to date. In this study, we profiled lncRNA expressions in 176 adult patients with primary MDS, and identified 4 lncRNAs whose expression levels were significantly associated with overall survival (OS). We then constructed a risk-scoring system with the weighted sum of these 4 lncRNAs. Higher lncRNA scores were associated with higher marrow blast percentages, higher-risk subtypes of MDSs (based on both the Revised International Prognostic Scoring System [IPSS-R] and WorldHealth Organization classification), complex cytogenetic changes, and mutations in RUNX1, ASXL1, TP53, SRSF2, and ZRSR2, whereas they were inversely correlated with SF3B1 mutation. Patients with higher lncRNA scores had a significantly shorter OS and a higher 5-year leukemic transformation rate compared with those with lower scores. The prognostic significance of our 4-lncRNA risk score could be validated in an independent MDS cohort. In multivariate analysis, higher lncRNA scores remained an independent unfavorable risk factor for OS (relative risk, 4.783; P , .001) irrespective of age, cytogenetics, IPSS-R, and gene mutations. To our knowledge, this is the first report to provide a lncRNA platform for risk stratification of MDS patients. In conclusion, our integrated 4-lncRNA risk-scoring system is correlated with distinctive clinical and biological features in MDS patients, and serves as an independent prognostic factor for survival and leukemic transformation. This concise yet powerful lncRNA-based scoring system holds the potential to improve the current risk stratification of MDS patients.

show abstract

“…It was found to be highly expressed in a series of human tumors, including breast and ovarian cancers, acute myeloid leukemia, and Hodgkin lymphoma. [19][20][21] Nonetheless, the expression and biological effect of PVT1 on glioma vascular endothelial cells remain unknown.…”

Section: Pvt1 Affects Growth Of Glioma Microvascular Endothelial Cellmentioning

confidence: 99%

PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186

Wang

Xue

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Vigorous angiogenesis is one of the reasons for the poor prognosis of glioma. A number of studies have shown that long non-coding RNA can affect a variety of biological behaviors of tumors. However, the influence of long non-coding RNAs on glioma vascular endothelial cells remains unclear. To simulate the glioma microenvironment, we applied glioma-conditioned medium to human cerebral microvascular endothelial cells. The long non-coding RNA PVT1 was found to be highly expressed in glioma vascular endothelial cells. Cell Counting Kit-8, migration, and tube formation assays showed that PVT1 overexpression promoted glioma vascular endothelial cells proliferation, migration, and angiogenesis. We also found that PVT1 overexpression upregulated the expression of the autophagy-related proteins Atg7 and Beclin1, which induced protective autophagy. Bioinformatics software and dual-luciferase system analysis confirmed that PVT1 acts by targeting miR-186. In addition, our study showed that miR-186 could target the 3′ untranslated region of Atg7 and Beclin1 to decrease their expression levels, thereby inhibiting glioma-conditioned human cerebral microvascular endothelial cell autophagy. In conclusion, PVT1 overexpression increased the expression of Atg7 and Beclin1 by targeting miR-186, which induced protective autophagy, thus promoting glioma vascular endothelial cell proliferation, migration, and angiogenesis. Therefore, PVT1 and miR-186 can provide new therapeutic targets for future anti-angiogenic treatment of glioma.

show abstract

Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia

Cited by 98 publications

References 47 publications

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes

PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186

Contact Info

Product

Resources

About